Skip to main content
    T

    Tela Bio Inc (TELA)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.76
    -0.06 (-7.13%)

    Market Cap: $37.06M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Tela Bio Inc (TELA) Earnings: Report Dates and Results

    Updated Nov 10, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Tela Bio (TELA) is expected to report earnings on Mar 22, 2027. In the quarter ended Sep 30, 2026, Tela Bio reported EPS of -$0.13, above the -$0.19 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    27%(8/30)
    Avg Surprise
    -10.41%
    Streak
    1 Q

    Upcoming Estimates

    Reports Mar 22, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.12
    Range-$0.12 - -$0.12
    5 analysts
    Revenue Consensus
    $20.29M
    Range$18.82M - $22.25M
    5 analysts
    Reports May 10, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.11
    Range-$0.12 - -$0.10
    2 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago-$0.13+13.2%
    60d ago-$0.12+5.7%
    30d ago-$0.12+4.3%
    7d ago-$0.110.0%
    Current-$0.11
    Revenue Consensus
    $20.01M
    Range$19.40M - $21.34M
    4 analysts

    Next Report

    TELA has an expected report date of Mar 22, 2027.

    TELA Earnings Call

    The latest TELA earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 30 quarters below that had an estimate, TELA beat 8, missed 21 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $18.96M, down 8.4% from $20.69M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.13-$0.19-$0.21 - -$0.13+31.58%BeatN/A54 up, 1 downNov 10, 2026$18.96M
    Jun 30, 2026-$0.20-$0.17-$0.20 - -$0.15-17.65%MissN/A50 up, 1 downAug 10, 2026$19.29M
    Mar 31, 2026-$0.21-$0.15-$0.24 - -$0.14-39.86%MissN/A51 up, 0 downMay 12, 2026$19.06M
    Dec 31, 2025-$0.17-$0.18-$0.19 - -$0.16+5.56%BeatN/A51 up, 4 downMar 25, 2026$20.87M
    Sep 30, 2025-$0.19-$0.20-$0.22 - -$0.20+5.00%BeatN/A40 up, 1 downNov 13, 2025$20.69M
    Jun 30, 2025-$0.22-$0.18-$0.20 - -$0.18-22.22%MissN/A42 up, 2 downAug 11, 2025$20.20M
    Mar 31, 2025-$0.25-$0.21-$0.27 - -$0.15-19.05%MissN/A42 up, 1 downMay 8, 2025$18.52M
    Dec 31, 2024-$0.23-$0.22-$0.29 - -$0.16-3.60%MissN/A52 up, 0 downMar 20, 2025$17.65M
    Sep 30, 2024-$0.42-$0.42-$0.44 - -$0.310.00%In lineN/A52 up, 0 downNov 7, 2024$18.96M
    Jun 30, 2024-$0.51-$0.47-$0.51 - -$0.43-8.51%MissN/A50 up, 0 downAug 12, 2024$16.09M
    Mar 31, 2024-$0.54-$0.51-$0.53 - -$0.46-5.88%MissN/A51 up, 0 downMay 9, 2024$16.60M
    Dec 31, 2023-$0.53-$0.43-$0.46 - -$0.42-23.26%MissN/A50 up, 0 downMar 21, 2024$17.00M
    Sep 30, 2023-$0.45-$0.27N/A-66.67%MissN/A50 up, 0 downNov 9, 2023$15.05M
    Jun 30, 2023-$0.46-$0.52-$0.58 - -$0.46+11.54%BeatN/A50 up, 0 downAug 9, 2023$14.49M
    Mar 31, 2023-$0.63-$0.56-$0.61 - -$0.49-12.50%MissN/A50 up, 0 downMay 11, 2023$11.91M
    Dec 31, 2022-$0.52-$0.54-$0.61 - -$0.49+3.70%BeatN/A50 up, 0 downMar 21, 2023$11.62M
    Sep 30, 2022-$0.64-$0.56-$0.72 - -$0.56-14.29%MissN/A40 up, 0 downNov 9, 2022$11.16M
    Jun 30, 2022-$0.79-$0.62-$0.69 - -$0.55-27.42%MissN/A50 up, 0 downAug 10, 2022$10.41M
    Mar 31, 2022-$0.75-$0.56-$0.65 - -$0.44-33.93%MissN/A40 up, 0 downMay 10, 2022$8.23M
    Dec 31, 2021-$0.59-$0.55-$0.62 - -$0.45-7.27%MissN/A40 up, 0 downMar 21, 2022$8.37M
    Sep 30, 2021-$0.57-$0.52-$0.59 - -$0.44-9.62%MissN/A4N/ANov 10, 2021$7.65M
    Jun 30, 2021-$0.57-$0.52-$0.56 - -$0.44-9.62%MissN/A4N/AAug 11, 2021$7.56M
    Mar 31, 2021-$0.56-$0.48-$0.53 - -$0.37-16.67%MissN/A4N/AMay 13, 2021$5.88M
    Dec 31, 2020-$0.54-$0.49-$0.53 - -$0.42-10.20%MissN/A4N/AMar 24, 2021$5.67M
    Sep 30, 2020-$0.53-$0.48-$0.62 - -$0.38-10.42%MissN/A4N/ANov 11, 2020$5.31M
    Jun 30, 2020-$0.53-$0.59-$0.67 - -$0.54+10.17%BeatN/A4N/AAug 12, 2020$3.51M
    Mar 31, 2020-$0.63-$0.56-$0.60 - -$0.53-12.50%MissN/A4N/AMay 12, 2020$3.73M
    Dec 31, 2019-$0.57-$0.59-$0.65 - -$0.57+3.39%BeatN/A4N/AMar 27, 2020$4.86M
    Sep 30, 2019-$0.59-$0.45-$0.78 - -$0.44-31.11%MissN/A3N/ANov 8, 2019$3.97M
    Jun 30, 2019-$0.47-$0.58N/A+18.97%BeatN/AN/AN/AAug 28, 2019$3.30M
    Last 30 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.83, after -$1.70 the year before. It was -$1.63 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.83N/A
    Dec 31, 2024-$1.70N/A
    Dec 31, 2023-$2.07N/A
    Dec 31, 2022-$2.70N/A
    Dec 31, 2021-$2.29N/A
    Dec 31, 2020-$2.23N/A
    Dec 31, 2019-$1.63N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,500 words across 9 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,4679
    2026Q2Jun 30, 20264,39812
    2026Q1Mar 31, 20265,55110
    2025Q4Dec 31, 20258,40410
    2025Q3Sep 30, 20254,24910
    2025Q2Jun 30, 20255,1829
    2025Q1Mar 31, 20254,1248
    2024Q4Dec 31, 20247,5139

    2026Q3 Earnings Call

    Opening remarks

    Louisa Smith Investor Relations Thank you, operator, and good afternoon, everyone. Earlier today, TELA Bio released financial results for the third quarter ended September 30, 2026. A copy of the press release is available on the company's website. Joining me on today's call are Heather Getz, Chief Executive Officer; Jeff Blizard, President; and Jim Hagen, Senior Vice President of Strategic Commercial Operations and Marketing. Before we begin, I'd like to remind you that during this conference call, the company may make projections and forward-looking statements regarding future events. We encourage you to review the company's past and future filings with the SEC, including, without limitation, the company's quarterly reports on Form 10-Q, which identify the specific risk factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, statements regarding product development, pipeline opportunities, sales and marketing strategies, and the impact of various additional risk factors as identified in our regulatory filings. Heather will begin with the Q3 results and the changes made to strengthen TELA Bio. Jeff will discuss the commercial performance, and then Heather will finish with a review of the financial results in more detail before we take your questions. With that, I'll now turn the call over to Heather.

    Heather Getz CEO Good afternoon, everyone, and thank you for joining us. Last week marked my 90th day as CEO of TELA Bio, and I want to use this time not just to walk through our Q3 results, but to share what I've learned, what's already in the process of being changed, and where we're headed. When I joined in August, I made a commitment to our Board, our employees, and all of you that I would listen first, but act swiftly to stabilize the company and extend our runway. Over these past 3 months, I have done just that. I've met with surgeons, investors, and employees across the organization. Three things became clear. First, we believe our core product portfolio is best-in-class at providing both value and performance and is supported by robust clinical data. Even more than I originally appreciated. I will be discussing today additional evidence of OviTex's outstanding clinical profile, which was issued recently. Second, our capital allocation needed to be much more focused. We've been spreading investments across too many initiatives and too quickly without clear prioritization. Third, when we adjusted our go-to-market strategy late last year, we created some gaps that also need to be addressed. The good news is that we have already made meaningful progress on addressing these items, as you will hear today. I'll start with the $17 million cost reduction plan commenced on September 1.

    Frequently Asked Questions About TELA

    When is Tela Bio's next earnings date?

    Tela Bio's next earnings report is expected for Mar 22, 2027.

    Did TELA beat earnings estimates last quarter?

    Yes. Tela Bio reported EPS of -$0.13 for the quarter ended Sep 30, 2026, above the -$0.19 estimate, a 31.58% surprise.

    What EPS do analysts expect from TELA next quarter?

    The consensus EPS estimate for Tela Bio for the quarter ending Dec 31, 2026 is -$0.12 from 5 analysts, with estimates from -$0.12 to -$0.12.

    How often does TELA beat earnings estimates?

    Tela Bio beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -7.53%.